# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025Program w...
LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company focused on developi...
Prestigious European Society for Medical Oncology Conference "trials-in-progress" sessionPivotal OVATION 3 trial of its...
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treatedLAWRENCEVILLE, N.J., Sept. ...